Moderna, Inc.
Moderna, Inc. (MRNA) is a biotechnology company centred on messenger RNA (mRNA) technology, best known for its COVID‑19 vaccine. The company applies its platform to develop vaccines and therapeutics across infectious diseases (influenza, RSV, CMV) and oncology, aiming for faster design and scalable manufacturing. Investors should know Moderna’s prospects combine platform-driven upside with typical biotech risks: revenues can be lumpy, clinical trials are binary events, and regulatory approvals and competition (notably Pfizer/BioNTech) materially affect the outlook. The market capitalisation reflects the transition from pandemic-era demand to a broader commercial strategy. Moderna invests heavily in R&D and capacity, which can pressure margins in the near term but may support future growth if programmes succeed. This stock tends to be higher volatility and may suit investors with a longer timeframe and higher risk tolerance. This is general information, not personalised investment advice.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Moderna's stock with a target price of $43.15, indicating potential for growth.
Financial Health
Moderna is performing well with strong revenue and profitability, reflecting healthy financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring MRNA
Beyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: August 5, 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketPediatric Vaccine Rollout
This carefully selected group of stocks represents companies positioned to benefit from the full FDA approval of COVID-19 vaccines for at-risk children. Our professional analysts have identified opportunities across the entire value chain, from vaccine manufacturers to healthcare providers and clinical research organizations.
Published: July 11, 2025
Explore BasketBiotech's IP Moat
This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.
Published: July 11, 2025
Explore BasketBuffett's Billions: The Philanthropy Effect
Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.
Published: July 1, 2025
Explore BasketRestless Innovators
Companies that refuse to stand still, constantly pushing boundaries and redefining what's possible. These stocks have been carefully selected by our analysts for their relentless pursuit of innovation and potential for long-term growth.
Published: June 17, 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: May 29, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Platform-driven growth
Moderna’s mRNA platform can speed development and scale production, offering potential for new products — though trial outcomes and approvals remain uncertain.
Pipeline diversification
Programmes in flu, RSV, CMV and oncology could broaden revenue streams, but each faces clinical and regulatory hurdles that create binary outcomes.
Commercial dynamics
Post‑pandemic demand, pricing and competition shape future sales; market conditions can change quickly and past performance is no guarantee of future results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
